Sanofi Moves Up In MS With Frexalimab Success
Anti-CD40L Antibody Significantly Reduced Disease Activity
Executive Summary
Much of the focus on the French major’s MS pipeline has been on the BTK inhibitor tolebrutinib but promising Phase II data on frexalimab have caught the eye.
You may also be interested in...
Sanofi Tries To Win Skeptics Over To Its Immunology Masterplan
Investors balked at Sanofi plans to raise R&D spending and eat into profits, so CEO Paul Hudson and new R&D chief Houman Ashrafian need to convince doubters that its immunology focused plan will pay off.
Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
All Eyes On Sanofi’s MS Efforts As Aubagio Plummets Upon Generic Entries
The French firm’s ex-blockbuster multiple sclerosis drug, Aubagio, saw sales more than halve as generics made their mark, prompting the firm to tout recent developments for two pipeline contenders for the disease.